<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127421</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-215</org_study_id>
    <nct_id>NCT05127421</nct_id>
  </id_info>
  <brief_title>Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement</brief_title>
  <official_title>A Phase 2, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label&#xD;
      extension in adolescent and adult participants with atopic dermatitis and head and/or neck&#xD;
      involvement. It is intended to compare the efficacy and safety of ruxolitinib cream 1.5% BID&#xD;
      versus vehicle cream, then further evaluate ruxolitinib cream as maintenance during the open&#xD;
      label extension period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 22, 2021</start_date>
  <completion_date type="Anticipated">July 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is 2:1 assignment to rux and vehicle creams.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>4 week double-blind treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Double-Blind Period: Proportion of participants who achieve an EASI75 of the head and neck region</measure>
    <time_frame>Week 4</time_frame>
    <description>Defined as &gt;=75% improvement in Eczema Area and Severity Index (EASI) score of the head and neck region.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve an EASI75 of the head and neck region</measure>
    <time_frame>Weeks 2 and 8</time_frame>
    <description>Defined as &gt;=75% improvement in Eczema Area and Severity Index (EASI) score of the head and neck region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve overall EASI75</measure>
    <time_frame>Weeks 2, 4 and 8</time_frame>
    <description>Defined as ≥ 75% improvement in Eczema Area and Severity Index (EASI) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-related adverse events</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with ruxolitinib cream 1.5% or vehicle cream twice a day (BID) in a double-blind fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label Extension: Ruxolitiib cream 1.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Ruxoltinib cream 1.5% twice per day (BID) during the open label extension period. Participants who complete the double-blind period will continue into this open-label extension period for an additional 4 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib cream</intervention_name>
    <description>Ruxolitinib cream 1.5% applied twice a day (BID)&quot;</description>
    <arm_group_label>Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BID</arm_group_label>
    <arm_group_label>Open Label Extension: Ruxolitiib cream 1.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle cream applied twice a day (BID) to affected areas</description>
    <arm_group_label>Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with diagnosis of AD for at least 6 months.&#xD;
&#xD;
          -  Participants with an overall and a face and/or neck IGA score of 2 or 3 at screening&#xD;
             and baseline.&#xD;
&#xD;
          -  Participants with AD affecting the following at screening and baseline:&#xD;
&#xD;
               1. ≥ 0.5% of the total BSA on the face and/or neck&#xD;
&#xD;
               2. Up to a total of 20% BSA (face and/or neck plus other body areas)&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children based on the criteria outlined in&#xD;
             the protocol.&#xD;
&#xD;
          -  Further inclusion criteria apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have an unstable course of AD (spontaneously improving or rapidly&#xD;
             deteriorating) as determined by the investigator over the previous 4 weeks prior to&#xD;
             baseline.&#xD;
&#xD;
          -  Participants with concurrent conditions and history of other diseases such as&#xD;
             immunocompromised; chronic or acute infection requiring systemic treatments; active&#xD;
             acute skin infection; other concomitant skin conditions that may interfere with the&#xD;
             evaluation of AD or compromise participant safety; other types of eczema; chronic&#xD;
             asthma requiring high dose of inhaled corticosteroids.&#xD;
&#xD;
          -  Any serious illness or medical, physical, or psychiatric condition(s) that, in the&#xD;
             investigator's opinion, would interfere with full participation in the study,&#xD;
             including administration of study drug and attending required study visits; pose a&#xD;
             significant risk to the participant; or interfere with interpretation of study data.&#xD;
&#xD;
          -  Previous treatment with systemic or topical JAK inhibitors (eg, ruxolitinib,&#xD;
             tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).&#xD;
&#xD;
          -  Participants who are pregnant (or who are considering pregnancy) or lactating.&#xD;
&#xD;
          -  Laboratory values outside of the protocol -defined criteria&#xD;
&#xD;
          -  Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haq Nawaz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Science</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atopic dermatiits</keyword>
  <keyword>adolescent</keyword>
  <keyword>adults</keyword>
  <keyword>in-home</keyword>
  <keyword>telemedicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

